Navirel (Vinorelbine)

• Vinorelbine is indicated for specific solid tumour types within the oncology therapeutic pathway.
• Non‑small cell lung cancer: used to improve progression‑free survival in adult patients with advanced disease.
• Metastatic breast cancer: employed to control disease progression in patients previously treated with anthracyclines and taxanes.

• Vinorelbine binds to tubulin at the Vinca binding site, inhibiting microtubule polymerisation. This disruption prevents the formation of functional mitotic spindles, leading to cell‑cycle arrest in the M phase and ultimately triggering apoptosis of rapidly dividing cancer cells.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Nausea and vomiting: gastrointestinal upset common after infusion.
• Fatigue: persistent tiredness affecting daily activities.
• Alopecia: hair loss that may be temporary.
• Constipation: decreased bowel movements.
• Anemia: lowered red blood cell levels causing weakness.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Severe pulmonary toxicity: breathlessness or interstitial pneumonitis.
• Peripheral neuropathy: tingling or numbness in extremities.
• Cardiac toxicity: arrhythmias or reduced cardiac function.
• Anaphylactic reactions: severe allergic response needing immediate treatment.
• Thrombocytopenia: low platelet count leading to bleeding risk.

• Vinorelbine requires careful monitoring and specific safety measures before and during therapy.
• Monitor blood counts: perform regular CBCs to detect neutropenia and anemia.
• Assess liver function: adjust dosing in patients with hepatic impairment.
• Avoid concurrent myelosuppressive agents: reduce risk of severe bone‑marrow suppression.
• Use anti‑emetics prophylactically: mitigate nausea and vomiting associated with infusion.
• Pregnancy and lactation: contraindicated unless benefits outweigh potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinorelbine exposure.
• Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce therapeutic levels.
• Concurrent myelosuppressive chemotherapy: heighten risk of severe neutropenia.
• Live vaccines: risk of infection due to immunosuppression.
• Other Vinca alkaloids: additive neurotoxicity.

Moderate Interactions (Monitor Closely)

• Antiemetics such as ondansetron: may alter QT interval.
• Anticoagulants (warfarin, DOACs): monitor coagulation parameters.
• Diuretics: watch for electrolyte disturbances.
• CYP2D6 substrates: possible modest effect on metabolism.